Stahl A - Search Results

1

Esophageal cancer.

Wieder HA, Stahl A, Lordick F, Ott K. Wieder HA, et al. Among authors: stahl a. Recent Results Cancer Res. 2008;170:71-9. doi: 10.1007/978-3-540-31203-1_6. Recent Results Cancer Res. 2008. PMID: 18019618 Review. No abstract available.

2

Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.

Stahl A, Ott K, Schwaiger M, Weber WA. Stahl A, et al. Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1471-8. doi: 10.1007/s00259-004-1626-6. Epub 2004 Jul 15. Eur J Nucl Med Mol Imaging. 2004. PMID: 15257418

3

Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen.

Stahl A, Weber WA, Avril N, Schwaiger M. Stahl A, et al. Nuklearmedizin. 2000 Dec;39(8):241-5. Nuklearmedizin. 2000. PMID: 11189901

4

Excretion of FDG into saliva and its significance for PET imaging.

Stahl A, Dzewas B, Schwaiger M, Weber WA. Stahl A, et al. Nuklearmedizin. 2002 Oct;41(5):214-6. Nuklearmedizin. 2002. PMID: 12418306

5

[Nuclear medical diagnostics for liver tumors].

Buck AK, Stollfuss JC, Stahl A, Beer AJ, Meisetschläger G, Schwaiger M. Buck AK, et al. Among authors: stahl a. Internist (Berl). 2007 Jan;48(1):21-4, 26-9. doi: 10.1007/s00108-006-1769-6. Internist (Berl). 2007. PMID: 17195061 German.

6

FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding.

Stahl A, Stollfuss J, Ott K, Wieder H, Fink U, Schwaiger M, Weber WA. Stahl A, et al. Nuklearmedizin. 2005;44(6):249-55; quiz N55-6. Nuklearmedizin. 2005. PMID: 16400385

7

FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.

Buchbender C, Kuemmel S, Hoffmann O, Stahl AR, Kimmig R, Otterbach F, Ladd S, Koeninger A, Forsting M, Bockisch A, Antoch G, Heusner TA. Buchbender C, et al. Among authors: stahl ar. Acta Radiol. 2012 Jul;53(6):628-36. doi: 10.1258/ar.2012.110699. Epub 2012 Jul 3. Acta Radiol. 2012. PMID: 22761341

8

Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs.

Stahl AR, Heusner TA, Hartung V, Nagarajah J, Bockisch A, Hahn S, Antoch G, Jentzen W. Stahl AR, et al. J Nucl Med. 2011 Jan;52(1):18-23. doi: 10.2967/jnumed.110.077461. Epub 2010 Dec 13. J Nucl Med. 2011. PMID: 21149481

9

The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer.

Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA, Antoch G, Bockisch A, Kimmig R, Schmid KW, Stahl AR. Grabellus F, et al. Among authors: stahl ar. J Nucl Med. 2010 Aug;51(8):1191-7. doi: 10.2967/jnumed.110.075721. J Nucl Med. 2010. PMID: 20679470

10

Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development?

Heusner TA, Hahn S, Hamami ME, Kögel S, Forsting M, Bockisch A, Antoch G, Stahl AR. Heusner TA, et al. Among authors: stahl ar. Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1397-406. doi: 10.1007/s00259-009-1113-1. Epub 2009 Mar 21. Eur J Nucl Med Mol Imaging. 2009. PMID: 19305995

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results